A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Clinical trial NCT06100874 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06100874
Sponsor: Adrienne G. Waks
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Her 2 Positive Breast Cancer Breast Cancer Female Breast Cancer Metastatic

Start date: 2023-11-20
Primary completion: 2026-02-09
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.